Cargando…

Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT

Allogeneic hematopoietic stem cell transplantation is a potentially curative procedure for many malignant diseases. Donor T cells prevent disease recurrence via graft-versus-leukemia (GVL) effect. Donor T cells also contribute to graft-versus-host disease (GVHD), a debilitating and potentially fatal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mammadli, Mahinbanu, Huang, Weishan, Harris, Rebecca, Sultana, Aisha, Cheng, Ying, Tong, Wei, Pu, Jeffery, Gentile, Teresa, Dsouza, Shanti, Yang, Qi, Bah, Alaji, August, Avery, Karimi, Mobin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726260/ https://www.ncbi.nlm.nih.gov/pubmed/33324410 http://dx.doi.org/10.3389/fimmu.2020.593863

Ejemplares similares

Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT
por: Mammadli, Mahinbanu, et al.
Publicado: (2021)

Interleukin‐2‐inducible T‐cell kinase (Itk) signaling regulates potent noncanonical regulatory T cells
por: Mammadli, Mahinbanu, et al.
Publicado: (2021)

TCF-1 Is Required for CD4 T Cell Persistence Functions during AlloImmunity
por: Mammadli, Mahinbanu, et al.
Publicado: (2023)

CrkL is required for donor T cell migration to GvHD target organs
por: Roy, Nathan H., et al.
Publicado: (2020)

A nomogram model for predicting ocular GVHD following allo-HSCT based on risk factors
por: Wang, Wen-hui, et al.
Publicado: (2023)

PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients
por: Hossain, Mohammad S., et al.
Publicado: (2017)

Human Wnt/β-Catenin Regulates Alloimmune Signaling during Allogeneic Transplantation
por: Mammadli, Mahinbanu, et al.
Publicado: (2021)

Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80
por: Cassady, Kaniel, et al.
Publicado: (2018)

The mechanistic study behind suppression of GVHD while retaining GVL activities by myeloid-derived suppressor cells.
por: Zhang, Jilu, et al.
Publicado: (2019)

Therapeutic Effects of HLA-G5 Overexpressing hAMSCs on aGVHD After Allo-HSCT: Involving in the Gut Microbiota at the Intestinal Barrier
por: Bu, Xiaoyin, et al.
Publicado: (2023)

Human Amniotic Mesenchymal Stem Cells Alleviate aGVHD after allo-HSCT by Regulating Interactions between Gut Microbiota and Intestinal Immunity
por: Bu, Xiaoyin, et al.
Publicado: (2023)

Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation
por: Song, Yuan, et al.
Publicado: (2020)

Reduced dose of PTCy followed by adjuvant α-galactosylceramide enhances GVL effect without sacrificing GVHD suppression
por: Nakamura, Makoto, et al.
Publicado: (2021)

PB2208: CAR-T TREATMENT POST FIRST ALLO-HSCT FAILURE MAY HAVE DIFFERENT PROCESSION COMPARING TO CAR-T BEFORE ALLO-HSCT
por: wang, D., et al.
Publicado: (2022)

Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation
por: Toubai, Tomomi, et al.
Publicado: (2015)

TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses
por: Harris, Rebecca, et al.
Publicado: (2022)

ITK signaling regulates a switch between T helper 17 and T regulatory cell lineages via a calcium-mediated pathway
por: Anannya, Orchi, et al.
Publicado: (2023)

Pathophysiology of GvHD and Other HSCT-Related Major Complications
por: Ghimire, Sakhila, et al.
Publicado: (2017)

Targeting ITK signaling for T cell-mediated diseases
por: Weeks, Samuel, et al.
Publicado: (2021)

Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity
por: Song, Qingxiao, et al.
Publicado: (2022)

Accumulation of T-cell-suppressive PD-L1(high) extracellular vesicles is associated with GvHD and might impact GvL efficacy
por: Baur, Rebecca, et al.
Publicado: (2023)

ITK signalling via the Ras/IRF4 pathway regulates the development and function of Tr1 cells
por: Huang, Weishan, et al.
Publicado: (2017)

Family caregivers’ support needs during allo-HSCT—a longitudinal study
por: Kisch, Annika M., et al.
Publicado: (2020)

Cytokine Overproduction and Immune System Dysregulation in alloHSCT and COVID-19 Patients
por: Lange, Andrzej, et al.
Publicado: (2021)

Author Correction: ITK signalling via the Ras/IRF4 pathway regulates the development and function of Tr1 cells
por: Huang, Weishan, et al.
Publicado: (2020)

The tyrosine kinase Itk suppresses CD8(+) memory T cell development in response to bacterial infection
por: Huang, Fei, et al.
Publicado: (2015)

PB2441: CD34+ CELL DOSE EFFECTS ON CLINICAL OUTCOMES OF ALLO-HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)
por: Zhou, Shengnan, et al.
Publicado: (2023)

Blockade of Vascular Endothelial Growth Factor (VEGF) Aggravates the Severity of Acute Graft-versus-host Disease (GVHD) after Experimental Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
por: Kim, Ai-Ran, et al.
Publicado: (2011)

Oral Cancer in HSCT Pediatric Patients Arising on GVHD: A Comprehensive Review
por: Cantile, Tiziana, et al.
Publicado: (2022)

Polymyositis as a manifestation of chronic graft‐versus‐host disease after allo‐HSCT
por: Meng, Lijuan, et al.
Publicado: (2018)

Dissecting the regulatory network of transcription factors in T cell phenotype/functioning during GVHD and GVT
por: Harris, Rebecca, et al.
Publicado: (2023)

T-Bet independent development of IFNγ secreting natural T helper 1 cell population in the absence of Itk
por: Kannan, Arun K., et al.
Publicado: (2017)

Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers
por: Li, Yan-Ruide, et al.
Publicado: (2022)

Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT
por: Zhang, Xiao-Hui, et al.
Publicado: (2015)

Development of a Nomogram for Predicting the Cumulative Incidence of Disease Recurrence of AML After Allo-HSCT
por: Zhang, Tongtong, et al.
Publicado: (2021)

Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?
por: Wang, Luxiang, et al.
Publicado: (2023)

Early myeloid-derived suppressor cells (HLA-DR(−)/(low)CD33(+)CD16(−)) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT
por: Wang, Ke, et al.
Publicado: (2019)

ITK independent development of Th17 responses during hypersensitivity pneumonitis driven lung inflammation
por: Elmore, Jessica, et al.
Publicado: (2022)

Allo-HSCT compared with immunosuppressive therapy for acquired aplastic anemia: a system review and meta-analysis
por: Zhu, Yangmin, et al.
Publicado: (2020)

Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study
por: Willasch, Andre Manfred, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u87rh6qafoul577t6blfrmsvo7